|
Match
|
Document |
Document Title |
|
|
7615535 |
Inhibiting GS-FDH to modulate no bioactivity
Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of...
|
|
|
7608592 |
HCV inhibitors
The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating...
|
|
|
7608591 |
Targeted delivery to legumain-expressing cells
The present invention relates to new agents and methods useful for preventing, treating and diagnosing diseases such as cancer. For example, the invention relates to prodrug agents useful for...
|
|
|
7608590 |
HCV NS-3 serine protease inhibitors
Compounds of the formula
where the variables are as defined in the specification inhibit the NS3 protease of flavivirus such as hepatitis C virus (HCV). The compounds comprise a novel linkage...
|
|
|
7605126 |
Acylaminoheteroaryl hepatitis C virus protease inhibitors
The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit serine protease activity, particularly the...
|
|
|
7598342 |
Alpha-fetoprotein peptides and uses thereof
The invention relates to compounds that include peptide and peptidomimetics that inhibit estrogen receptor dependent cell proliferation. The compounds of the invention are useful for treating cell...
|
|
|
7598224 |
Dual chain synthetic heparin-binding growth factor analogs
The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties...
|
|
|
7595299 |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses...
|
|
|
7592316 |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses...
|
|
|
7585845 |
Hepatitis C inhibitor compounds
Compounds of formula (I):
wherein B, X, R 3 , L 0 , L 1 , L 2 , R 2 , R 1 and R C are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis...
|
|
|
7582605 |
Phosphorus-containing hepatitis C serine protease inhibitors
The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity,...
|
|
|
7582312 |
Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
Methods of producing lung surfactant formulations through solvent dissolution and lyophilization are described as well as surfactant formulations derived therefrom. Methods of treating respiratory...
|
|
|
7579319 |
Methods for improving the structure and function of arterioles
The present invention relates to the unexpected finding that vessels smaller than even the smallest arteries (i.e. arterioles) thicken, become dysfunctional and cause end organ damage to tissues as...
|
|
|
7576175 |
Alpha-4 beta-1 integrin ligands for imaging and therapy
The present invention provides α 4 β 1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino...
|
|
|
7576062 |
Compounds with growth hormone releasing properties
Disclosed are compounds of formula I
wherein R 1 , R 2 , R 5 , R 6 , R 7 , R 8 , G, J, L, M, a, b, c, d, e, and f are as defined in the specification, and compositions containing them. These...
|
|
|
7576061 |
Methods for preventing mitochondrial permeability transition
The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at...
|
|
|
7575856 |
Compositions and methods for the evaluation and resuscitation of cadaveric hearts for transplant
The present invention describes devices, solutions, and methods for the ex-vivo assessment, resuscitation, triage, and maintenance of human candidate cadaveric hearts.
|
|
|
7569548 |
Method of preparing peptide
The present invention provides a method of preparing an intermediate for LHRH antagonists, which requires fewer steps than conventional methods and provides the intermediate in high yield and high...
|
|
|
7569547 |
Inhibiting furin with polybasic peptides
Small, polybasic peptides are disclosed that are effective as furin inhibitors, e.g. hexa- to nona-peptides having L-Arg or L-Lys in most positions. Removing the peptide terminating groups can...
|
|
|
7560433 |
Treatment of multiple sclerosis (MS)
The invention relates to the treatment multiple sclerosis, and in particular to the treatment of the inflammatory injury seen in the progressive stages in the disease such as seen with the...
|
|
|
7557088 |
Methods and compositions for treating conditions
The invention relates to compositions that can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such...
|
|
|
7550559 |
Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses...
|
|
|
7550439 |
Methods for reducing oxidative damage
The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic...
|
|
|
7547676 |
Antagonist peptides to the C5A chemotactic function of vitamin D binding protein
It has been demonstrated that one of Vitamin D Binding Protein (DBP) biological functions is to enhance the chemotactic activity of C5 a and C5 a des Arg. The present invention has found that...
|
|
|
7544662 |
Polypeptides useful for appetite suppression
The present invention relates to polypeptides obtained from bear derivative isolate which are useful in suppressing appetite. The polypeptides of the present invention are most preferably between...
|
|
|
7541340 |
Methods for reducing CD36 expression
The invention provides a method of reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net...
|
|
|
7541157 |
Method of screening groups of radioactive molecules and applications thereof
The invention relates to an amplification-free method of screening groups of radioactive molecules, comprising at least the following steps: (1) the group of molecules is administered to at least...
|
|
|
7538091 |
Intracellular delivery of biological effectors
The invention relates to a sequence of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novel...
|
|
|
7534438 |
Product and process for liquefaction of mucus or sputum
Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The...
|
|
|
7534431 |
Methods and compositions for administering therapeutic and diagnostic agents
Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.
|
|
|
7528228 |
Method for synthesizing peptides comprising at least one glycine molecule
Method for preparing a peptide or a peptide derivative comprising at least 2 enantiopure amino acids and at least one glycine molecule, comprising the reaction of a compound of general formula XCH...
|
|
|
7524820 |
Compounds of therapeutic value in the treatment of multiple sclerosis and other diseases wherein foamy cells are involved in the disease etiology
The invention provides a method for assessing or determining activity of a test compound on modulation of gene product levels comprising culturing cells, contacting at least one of the cultured...
|
|
|
7521427 |
Peptidyl allyl sulfones
The present disclosure provides compositions for inhibiting proteases, methods for synthesizing the compositions, and methods of using the disclosed protease inhibitors. Aspects of the disclosure...
|
|
|
7517857 |
Immune-modulating peptide
Disclosed are peptides having SEQ ID NOs: 1 to 24 that induce superoxide generation by human monocytes or neutrophils; that induce an intracellular calcium increase by human peripheral blood...
|
|
|
7517855 |
Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
The present invention relates generally to peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, methods of making peptides, which inhibit angiogenesis, cell...
|
|
|
7514557 |
Process for preparing acyclic HCV protease inhibitors
Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection:
The disclosed...
|
|
|
7507719 |
Use of peptidic conjugates for preparing compositions for alopecia preventive and curative treatment
The invention relates to the use of peptidic conjugates containing Gly-His-Lys for producing dermatological or cosmetological compositions for stimulating hair growth or stopping hair fall.
|
|
|
7504092 |
Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes
A peptide, with the sequence (AA)n-Arg-Gly-Ser-(AA)n, where (AA) is any amino acid or a derivative thereof and n=0 to 3, as an active ingredient in or for the preparation of a cosmetic and/or...
|
|
|
7498406 |
Substantially cell membrane impermeable compound and use thereof
The present invention relates to a compound according to Formula (I): A-(L-Y) p , wherein A comprises at least one substantially cell- membrane impermeable pendant group; L comprises any suitable...
|
|
|
7498310 |
Cosmetic or dermatological preparations comprising oligopeptides for lightening the skin of age marks and/or for preventing tanning of the skin, in particular tanning of the skin caused by UV radiation
Cosmetic or pharmaceutical preparations which are distinguished by an effective content of one or more monomeric or homo- or heterodimer or homo- or heterotrimeric or homo- or heterotetrameric...
|
|
|
7491704 |
Compounds for enzyme inhibition
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of...
|
|
|
7491703 |
Tetrapeptide regulating blood glucose level in diabetes mellitus
The invention refers to the field of medicine and can be applied as a substance capable of regulating glucose level while treating and preventing diabetes mellitus. There is proposed a biologically...
|
|
|
7491699 |
Peptide nanostructures and methods of generating and using the same
A tubular or spherical nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids...
|
|
|
7485625 |
Inhibitors of hepatitis C virus NS3/NS4a serine protease
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses...
|
|
|
7482024 |
Compositions comprising an active agent
The present invention provides a highly dispersible formulation comprising an active agent and a dipeptide or tripeptide comprising at least two leucyl residues. The composition of the invention...
|
|
|
7476650 |
Enzyme inhibition
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of...
|
|
|
7473760 |
Cyclic peptide compositions for treatment of sexual dysfunction
A cyclic peptide of the structural formula:
or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 5 , R 6 , m, n and p are as defined. Further provided are compositions for...
|
|
|
7470664 |
HCV NS3 protease inhibitors
The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or...
|
|
|
7468354 |
Tissue specific prodrugs
The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA). These prodrugs are useful for substantially inhibiting...
|
|
|
7465710 |
Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
This invention relates generally to dipeptides and tripeptides and to methods for pharmaceutical treatment of mammals using analogs of such dipeptides and tripeptides. More specifically, the...
|